FIELD: medicine.
SUBSTANCE: offered is application Aplydine for production of medical product for leukaemia or lymphoma treatment by means of combined therapy using Aplydine and other medical product chosen from group consisting of methotrexate, cytosine arabinoside, mythoxanthrone, vynblastine, methylprennisolone and doxyrubicine, related methods of treatment (versions), pharmaceutical composition and kit. Cancer synergism of listed agents is shown in combination with Aplydine.
EFFECT: provision of effective treatment of fumours.
34 cl, 15 dwg, 6 ex, 11 tbl
Title | Year | Author | Number |
---|---|---|---|
IMPROVED METHODS FOR TREATING TUMOURS | 2007 |
|
RU2481853C2 |
METHODS FOR PERSONALIZED MEDICAL TESTING EX VIVO FOR HEMATOLOGICAL NEOPLASMS | 2010 |
|
RU2636614C2 |
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2011 |
|
RU2743643C2 |
TREATMENT OF MALIGNANT TUMOR WITH APLIDINE | 2000 |
|
RU2261104C2 |
COMBINATION THERAPY WITH AN ANTITUMOR ALKALOID | 2011 |
|
RU2605335C2 |
COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
COMBINATION THERAPY WITH ANTITUMOR ALKALOID | 2018 |
|
RU2757373C2 |
COMBINATIONS OF SPECIFIC CLASS I HISTONE DEACETYLASE INHIBITORS AND PROTEASOME INHIBITORS | 2007 |
|
RU2456990C2 |
CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | 2011 |
|
RU2602878C2 |
CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | 2016 |
|
RU2678818C2 |
Authors
Dates
2008-12-20—Published
2004-03-12—Filed